Abstract This multicenter, retrospective study evaluated the efficacy and safety of the venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony‐stimulating factor (VD‐CAG) regimen in newly diagnosed acute myeloid leukemia (ND‐AML) patients aged 18–60. The analysis included, but was not limited to, the composite complete response (CRc) rate, measurable residual disease (MRD) negativity rate, overall survival (OS), event‐free survival (EFS), and safety. A total of 107 adult patients with AML were included in the study, conducted between March 1, 2022, and December 31, 2024. The median age was 49 years (range: 18–60 years), with a male‐to‐female ratio of 44:63. The CRc rate after one cycle of the VD‐CAG regimen was 86.9% (95% CI 79–92.7; 93 of 107 patients) in the entire cohort. 73 (79%) of 93 patients who reached CRc had undetectable MRD. Grade 3 or worse adverse events included neutropenia in 107 (100%) of 107 patients, thrombocytopenia in 107 (100%), anemia in 107 (100%), febrile neutropenia in 57 (53%), pneumonia in 10 (9.3%), sepsis in five (4.7%), and tumor lysis syndrome in three (2.8%). No treatment‐related deaths occurred. With a median follow‐up of 8.8 months (range: 1–33.5 months), the median EFS and OS are not reached. The estimated 12‐month OS was 90% (95% CI 90–95) and 12‐month EFS was 79% (95% CI 69–87). The VD‐CAG regimen represents an effective induction therapy for young ND‐AML. It leads to high rates of CRc and MRD‐negative remissions, along with encouraging OS and EFS across prognostic subgroups.
Zhang et al. (2025) studied this question.